3.1. FDA Approved HDAC Inhibitors and the Mitochondrial Chaperone Inhibitor, Gamitrinib, Lead to a Synergistic Reduction of Cellular Viability in Glioblastoma Models. Here, HDAC9 is linked to glioblastoma.